|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016441,
umls-concept:C0247025,
umls-concept:C0288672,
umls-concept:C0439231,
umls-concept:C0439851,
umls-concept:C0522523,
umls-concept:C0522776,
umls-concept:C0581603,
umls-concept:C1274040,
umls-concept:C1521840,
umls-concept:C1522318,
umls-concept:C1552596,
umls-concept:C1707455,
umls-concept:C1947931
|
|
pubmed:issue |
9330
|
|
pubmed:dateCreated |
2002-9-20
|
|
pubmed:abstractText |
Two placebo-controlled trials testing intravenous platelet glycoprotein IIb/IIIa antagonists in the setting of percutaneous coronary revascularisation with intracoronary stents have shown a durable reduction in ischaemic events to 6 months. These trials differed regarding their patient population, IIb/IIIa inhibitor, and reported extent of benefit. Whether a small-molecule agent affecting only the IIb/IIIa receptor would provide a similar outcome for ischaemic events and clinical restenosis at 6 months when directly compared with a monoclonal antibody known to affect several integrin receptors is unknown.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
pubmed-author:ArdissinoDiegoD,
pubmed-author:BassandJean-PierreJP,
pubmed-author:BorziLynnL,
pubmed-author:DemopoulosLaura ALA,
pubmed-author:DiBattistePeter MPM,
pubmed-author:HarrisKatherine AKA,
pubmed-author:HerrmannHoward CHC,
pubmed-author:MacayaCarlosC,
pubmed-author:MoliternoDavid JDJ,
pubmed-author:NeumannFranz-JosefFJ,
pubmed-author:StoneGregg WGW,
pubmed-author:TARGET investigators,
pubmed-author:TopolEric JEJ,
pubmed-author:YakubovSteven JSJ,
pubmed-author:YeungAlan CAC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
360
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
355-60
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12241774-Antibodies, Monoclonal,
pubmed-meshheading:12241774-Endpoint Determination,
pubmed-meshheading:12241774-Female,
pubmed-meshheading:12241774-Follow-Up Studies,
pubmed-meshheading:12241774-Humans,
pubmed-meshheading:12241774-Immunoglobulin Fab Fragments,
pubmed-meshheading:12241774-Male,
pubmed-meshheading:12241774-Myocardial Infarction,
pubmed-meshheading:12241774-Myocardial Revascularization,
pubmed-meshheading:12241774-Platelet Aggregation Inhibitors,
pubmed-meshheading:12241774-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:12241774-Randomized Controlled Trials as Topic,
pubmed-meshheading:12241774-Stents,
pubmed-meshheading:12241774-Treatment Outcome,
pubmed-meshheading:12241774-Tyrosine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
|
|
pubmed:affiliation |
Department of Cardiovascular Medicine and C5 (Cleveland Clinic Cardiovascular Coordinating Center), Cleveland Clinic Foundation, Cleveland, OH 44195, USA. molited@ccf.org
|
|
pubmed:publicationType |
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
